For the year ending 2025-12-31, BNGO has $73,584K in assets. $29,160K in debts. $2,990K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 2,990 | |||
| Investments | 16,279 | |||
| Accounts receivable, net | 5,200 | |||
| Inventory | 5,448 | |||
| Prepaid expenses and other current assets | 5,203 | |||
| Restricted investments | 10,266 | |||
| Total current assets | 45,386 | |||
| Restricted cash | 0 | |||
| Property and equipment, gross | 43,047 | |||
| Less accumulated depreciation and amortization | 28,200 | |||
| Property and equipment, net | 14,847 | |||
| Operating lease right-of-use assets | 3,217 | |||
| Finance lease right-of-use assets | 3,095 | |||
| Intangible assets, net | 4,345 | |||
| Other long-term assets | 2,694 | |||
| Total assets | 73,584 | |||
| Accounts payable | 5,590 | |||
| Accrued expenses | 5,460 | |||
| Contract liabilities | 967 | |||
| Operating lease liability | 697 | |||
| Finance lease liability | 249 | |||
| Convertible debentures payable (at fair value) | 9,979 | |||
| Total current liabilities | 22,942 | |||
| Operating lease liability, net of current portion | 2,489 | |||
| Finance lease liability, net of current portion | 3,480 | |||
| Long-term contract liabilities | 249 | |||
| Total liabilities | 29,160 | |||
| Common stock, 0.0001 par value 400,000,000 shares authorized at december 31, 2025 and 2024 10,740,200 and 1,865,400 shares issued and outstanding at december 31, 2025 and 2024, respectively | 1 | |||
| Additional paid-in capital | 764,026 | |||
| Accumulated deficit | -719,620 | |||
| Accumulated other comprehensive income | 17 | |||
| Total stockholders equity | 44,424 | |||
| Total liabilities and stockholders equity | 73,584 | |||
Bionano Genomics, Inc. (BNGO)
Bionano Genomics, Inc. (BNGO)